What is it about?

Scientists developed a dual epigenetic therapy that reactivates a gene to break down the protective fibrotic shell around aggressive prostate tumors, restoring treatment sensitivity (with over 90% tumor shrinkage) and enabling immune cells to attack the cancer—offering a practical new strategy for overcoming resistance in similar solid tumors.

Featured Image

Why is it important?

This study reveals a key epigenetic switch that drives lethal drug resistance in aggressive prostate cancer. A dual-targeted therapy dismantles the tumor’s protective fibrotic shell, achieving over 90% tumor shrinkage and reactivating anti-tumor immunity. Because the drugs are already clinically available, this strategy can be rapidly translated to patients. Importantly, it also offers a blueprint for overcoming stromal-mediated resistance in other ECM-rich solid tumors, potentially helping a much broader population of patients with few remaining options.

Perspectives

This work opens a direct path to clinical trials, as both EZH2 and DNMT inhibitors are already approved or in advanced testing. Beyond prostate cancer, the dual epigenetic strategy may be deployable against pancreatic, breast, and other ECM-rich solid tumors where a fibrotic stroma blocks therapy and immune entry. Biomarker-driven patient selection—based on the DNA methylation/H3K27me3 switch and ADAMTS1 silencing—could guide precision application. Combining this epigenetic approach with immunotherapy may further enhance durable responses, reshaping how stromal resistance is tackled in oncology.

Zhuangzhuang Zhang
Anhui Medical University

Read the Original

This page is a summary of: Targeting the DNA methylation–H3K27me3 switch reverses castration resistance and immunosuppression via ADAMTS1-driven collagenolysis, Proceedings of the National Academy of Sciences, June 2026, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2525431123.
You can read the full text:

Read

Contributors

The following have contributed to this page